Mathias Van Hemelrijck

Dr. Mathias Van Hemelrijck

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Vessel Plus
Verified
Journal Article
Open access
PDF file
MHMathias Van Hemelrijck
Mathias Van Hemelrijck
JSJuri Sromicki
Juri Sromicki
LHLars Husmann
Lars Husmann
ZRZoran Rancic
Zoran Rancic
BHBarbara Hasse
Barbara Hasse
TCThierry P. Carrel
Thierry P. Carrel
Vascular graft infections are rare complications after surgical and endovascular treatment of aortic diseases. This condition is characterized by complexity in diagnosis and medico-surgical management. Moreover, even if properly treated, morbidity and mortality rates are high. Although several advances have been made over the years and guidelines of treatment have been published, there is still debate on the optimal care for this disease. With local microbiological patterns and multiresistant strains conditioning antimicrobial treatment as well as several surgical debridement techniques in the armamentarium, it is difficult to offer recommendations that can be generalized for every single case. In this review, we aim at describing thoracic and abdominal vascular graft infections and providing current information on diagnosis, medical treatment, and surgical management.

16 January 2018 in F1000Research
Verified
Journal Article
Open access
PDF file
MHMathias Van Hemelrijck
Mathias Van Hemelrijck
MTMaurizio Taramasso
Maurizio Taramasso
CCCarlotta De Carlo
Carlotta De Carlo
SKShingo Kuwata
Shingo Kuwata
EREvelyn Regar
Evelyn Regar
FMFrancesco Maisano
Francesco Maisano
Over the last few years, treatment of severe symptomatic aortic stenosis in high-risk patients has drastically changed to adopt a less-invasive approach. Transcatheter aortic valve implantation (TAVI) has been developed as a very reproducible and safe procedure, as shown in many trials. When compared to surgery, TAVI has produced superior, or at least comparable, results, and thus a trend to broaden treatment indications to lower-risk patients has erupted as a natural consequence, even though there is a lack of long-term evidence. In this review, we summarize and underline aspects that still remain unanswered that are compulsory if we want to enhance our understanding of this disease.

24 August 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
MHMathias Van Hemelrijck
Mathias Van Hemelrijck
JSJuri Sromicki
Juri Sromicki
MFMichelle Frank
Michelle Frank
MGMatthias Greutmann
Matthias Greutmann
BLBruno Ledergerber
Bruno Ledergerber
BHBarbara Hasse
Barbara Hasse
Introduction: Around 25% of patients with left-sided infective endocarditis and operative indication do not undergo surgery. Baseline characteristics and outcomes are underreported. This study describes characteristics and outcomes of surgical candidates with surgical intervention or medical treatment only.Methods: Retrospective analysis of ongoing collected data from a single-center from an observational cohort of patients with infective endocarditis (ENVALVE). Kaplan-Meier estimates for survival was calculated. Factors associated with survival were assessed using a bivariable Cox model. To adjust for confounding by indication, uni- and multivariable logistic regression for the propensity to receive surgery were adjusted.Results: From January 2018 and December 2021, 154 patients were analyzed: 116 underwent surgery and 38 received medical treatment only. Surgical candidates without surgery were older (70 vs. 62 years, p = 0.001). They had higher preoperative risk profile (EuroSCORE II 14% (7.2–28.6) vs. 5.8% (2.5–20.3), p = 0.002) and more comorbidities. One patient was lost-to-follow-up. Survival analysis revealed a significant higher one-year survival rate among patients following surgery (83.7% vs. 15.3% in the non-surgical group; log-rank test <0.0001). In the final multivariable adjusted model, surgery was less likely among patients with liver cirrhosis [OR = 0.03 (95% CI 0.00–0.30)] and with hemodialysis [OR = 0.014 (95% CI 0.00–0.47)].Conclusion: Patients with left-sided infective endocarditis who do not undergo surgery despite an operative indication are older, have more comorbidities and therefore higher preoperative risk profile and a low 1-year survival. The role of the Endocarditis Team may be particularly important for the decision-making process in this specific group.

30 June 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
VZVirgile Zimmermann
Virgile Zimmermann
NFNicolas Fourré
Nicolas Fourré
BLBruno Ledergerber
Bruno Ledergerber
JEJana Epprecht
Jana Epprecht
BSBerit Siedentop
Berit Siedentop
Matthaios Papadimitriou-OlivgerisMatthaios Papadimitriou-Olivgeris
Matthaios Papadimitriou-Olivgeris
Background: Enterococci are a common cause of infective endocarditis (IE). This study aimed to assess the diagnostic performance of the 2015 and 2023 Duke versions of the European Society of Cardiology (ESC) Duke criteria, as well as the 2023 Duke International Society of Cardiovascular Infectious Diseases (ISCVID) clinical criteria, for identifying IE among patients with enterococcal bacteremia. Methods: We included adult retrospective patients with enterococcal bacteremia from 3 independent cohorts across 2 Swiss university hospitals between 2015 and 2024. An interdisciplinary Endocarditis Team classified each case as either IE or not IE. Each episode was then classified as definite, possible, or rejected IE according to the 2015 Duke-ESC, 2023 Duke-ESC, and 2023 Duke-ISCVID clinical criteria. Patients with IE (reference standard) classified as definite IE by the Duke criteria were considered true positives, while those without IE classified as rejected IE were considered true negatives. Results: Among 827 episodes with enterococcal bacteremia, IE was diagnosed in 173 (21%) episodes. The sensitivity of the 2015 Duke-ESC, 2023 Duke-ISCVID, and 2023 Duke-ESC clinical criteria for diagnosing IE was 67% (95% CI, 59%–74%), 79% (95% CI, 72%–85%), and 74% (95% CI, 67%–80%), respectively. Specificity was 86% (95% CI, 83%–89%) for the 2015 Duke-ESC criteria, 55% (95% CI, 51%–59%) for the 2023 Duke-ISCVID criteria, and 69% (95% CI, 65%–72%) for the 2023 Duke-ESC criteria. Conclusions: Among the evaluated Duke criteria versions, the 2023 Duke-ISCVID criteria demonstrated the highest sensitivity for diagnosing IE in patients with enterococcal bacteremia. However, this was at the expense of specificity.

8 March 2022 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
JSJuri Sromicki
Juri Sromicki
MHMathias Van Hemelrijck
Mathias Van Hemelrijck
MSMartin Oliver schmiady
Martin Oliver schmiady
BKBernard Krüger
Bernard Krüger
MMMohammed Morjan
Mohammed Morjan
CMCarlos A. Mestres
Carlos A. Mestres
Oral anticoagulation prior to emergency surgery is associated with an increased risk of perioperative bleeding, especially when this therapy cannot be discontinued or reversed in time. The goal of this study was to analyse the impact of different oral anticoagulants on the outcome of patients who underwent emergency surgery for acute type A aortic dissection (ATAAD). This was a single-centre retrospective study of patients treated with oral anticoagulation at the time of surgery for ATAAD. Outcomes of patients on new oral anticoagulant (NOAC) therapy were compared to respective outcomes of patients on Coumadin. Additionally, a survival analysis was performed comparing these 2 groups with patients who were operated on with no prior anticoagulation. Between January 2013 and April 2020, a total of 437 patients (63.8 ± 11.8 years, 68.4% male) received emergency surgery for ATAAD; 35 (8%) were taking oral anticoagulation at the time of hospital admission: 20 received phenprocoumon; 14, rivaroxaban; and 1, dabigatran. Compared to Coumadin, NOAC was associated with a greater need for blood-product transfusions and haemodynamic compromise. Operative mortality was 53% in the NOAC group and 30% in the Coumadin group. A 5-year survival analysis showed no significant difference between the NOAC and the Coumadin group (P = 0.059). Compared to 402 patients treated during the study period without anticoagulation, patients taking NOAC had significantly worse survival (P = 0.001), whereas that effect was not observed in patients undergoing surgery who were taking Coumadin (P = 0.99). Emergency surgery for ATAAD in patients taking NOAC is associated with high morbidity and mortality. NOAC are a major risk factor for uncontrollable bleeding and haemodynamic compromise. New treatment strategies must be defined to improve surgical outcomes in these high-risk patients.

10 September 2014 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
MHMathias Van Hemelrijck
Mathias Van Hemelrijck
JPJovana Pavicevic
Jovana Pavicevic
HTHerman Tolboom
Herman Tolboom
THTomas Holubec
Tomas Holubec
VFVolkmar Falk
Volkmar Falk
DRDiana Reser
Diana Reser
Background Minimally invasive direct coronary artery bypass grafting (MIDCAB) has gained wide acceptance for the treatment of single vessel disease of the left anterior descending artery (LAD). Here, we present our single center experience of 152 consecutive patients. Materials and Methods All patients underwent MIDCAB through a left anterior minithoracotomy between January 1, 2009, and December 31, 2012. Preoperative, intraoperative, postoperative, and follow-up data including major adverse cardiac and cerebrovascular events (MACCE) and need for re-intervention were collected. Results Mean age was 64.4 ± 11 years, median additive EuroSCORE 3 (0–11), 84% were male. All except one patient were successfully operated without cardiopulmonary bypass. Seven patients with unexpected severely calcified LADs were converted to sternotomy (4.6%); 91.3% were extubated in the operating room or on the day of surgery. Median stay at the intensive care unit and in hospital were 1 (0–97) and 7 (1–49) days, respectively. Thirty-day mortality was 1.9%. There was no stroke. Five patients (3.2%) had to be re-explored for bleeding and 95% received no transfusion. Median follow-up was 24 months (0–97) and complete in 93.3% with overall survival of 92.4 ± 0.2% and MACCE-free survival of 96.1 ± 1.7%. Two patients had a re-intervention of the LAD. Conclusion MIDCAB is a safe procedure with low postoperative morbidity, mortality, and favorable mid-term MACCE-free survival in selected patients that should be discussed in a heart team setting to evaluate the “ideal” individual treatment option.